Chronic obstructive pulmonary disease (COPD) is a major public health problem, causing a significant impairment in terms of disability and quality of life (QOL; [@bibr12-1557988320922630]; [@bibr17-1557988320922630]; [@bibr30-1557988320922630]; [@bibr46-1557988320922630]). Worldwide, COPD ranks among the top five causes of disability. COPD is predicted to become the third leading cause of mortality by 2030 and to be responsible for 7.8% of total deaths in the world ([@bibr32-1557988320922630]; [@bibr33-1557988320922630]). The diagnosis of COPD requires confirmation, via spirometry, of airflow limitation (AFL) that is not fully reversible ([@bibr9-1557988320922630]). Staging COPD AFL in terms of severity is a pioneer step in its management ([@bibr17-1557988320922630]; [@bibr52-1557988320922630]). The AFL staging is a predictor factor of mortality ([@bibr52-1557988320922630]). It is correlated with QOL impairment ([@bibr53-1557988320922630]) and has therapeutic implications ([@bibr52-1557988320922630]). Once the COPD AFL stage is determined, physicians are required to include their patients into one of the four refined "ABCD" groups of the Global Initiative for Chronic Obstructive Lung Disease ([@bibr17-1557988320922630]; based on dyspnea \[[@bibr14-1557988320922630]\], number of exacerbations, COPD assessment test \[CAT\] score \[[@bibr25-1557988320922630]\]) and to evaluate their QOL impairment ([@bibr17-1557988320922630]; [@bibr37-1557988320922630], [@bibr38-1557988320922630]). In practice, two questions related to the diagnosis and staging severity of COPD AFL should be addressed. The first question is almost resolved in the literature ([@bibr1-1557988320922630]; [@bibr9-1557988320922630]; [@bibr17-1557988320922630]; [@bibr39-1557988320922630]; [@bibr52-1557988320922630]; [@bibr62-1557988320922630]). A global consensus recommends defining COPD AFL when the post-bronchodilator ratio between forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC; FEV1/FVC ratio) is less than 0.70 ([@bibr1-1557988320922630]; [@bibr9-1557988320922630]; [@bibr17-1557988320922630]; [@bibr39-1557988320922630]; [@bibr52-1557988320922630]; [@bibr62-1557988320922630]). The answer to the second question is debatable.

While several scholarly societies agreed on staging COPD using the post-bronchodilator FEV~1~ ([@bibr1-1557988320922630]; [@bibr10-1557988320922630]; [@bibr17-1557988320922630]; [@bibr39-1557988320922630]; [@bibr52-1557988320922630]; [@bibr62-1557988320922630]), there is no clear consensus on how to express this parameter. In fact, several expressions were proposed ([@bibr17-1557988320922630]; [@bibr35-1557988320922630]; [@bibr36-1557988320922630]; [@bibr43-1557988320922630]). First, according to the [@bibr17-1557988320922630], the FEV~1~ should be expressed as the percentage of the predicted value derived from a predictive equation (FEV~1%pred~). Second, the global lung function initiative proposed to express the FEV~1~ as a z-score (FEV~1z-score~; [@bibr43-1557988320922630]). Third, other methods were advanced, such as standardizing the FEV~1~ by the power of height (FEV~1~/height^2^ [@bibr36-1557988320922630] or FEV~1~/height^3^ \[[@bibr35-1557988320922630]\]) or by the lowest sex-specific first percentile (FEV~1Quotient~; [@bibr35-1557988320922630]). While several studies have tested the value of the aforementioned classifications as predictors of survival and health outcomes ([@bibr19-1557988320922630]; [@bibr21-1557988320922630]; [@bibr40-1557988320922630]; [@bibr58-1557988320922630]), none has evaluated their utilities in terms of the refined "ABCD" assessment tool ([@bibr17-1557988320922630]) or in terms of their impact on the health status (e.g., via some QOL questionnaires such as the CAT \[[@bibr25-1557988320922630]\] or the VQ11 \[[@bibr37-1557988320922630], [@bibr38-1557988320922630]\]).

[@bibr18-1557988320922630] highlighted that it is time for the medical world to take COPD seriously. For that reason, and taking into account the aforementioned points, the aim of this study was to compare some relevant health outcomes \[i.e., the percentages of patients classified GOLD "C/D" and the scores of QOL questionnaires (CAT and VQ11)\] between COPD patients having "mild to moderate" and "severe to very severe" AFL according to the aforementioned five COPD AFL classifications.

Patients and Methods {#section1-1557988320922630}
====================

Study Design {#section2-1557988320922630}
------------

This cross-sectional prospective study was conducted at the Department of Physiology and Functional Explorations in (the Farhat HACHED University Hospital, Sousse-Tunisia). The study was performed during 2017 and 2018. Since all the performed tests (spirometry, questionnaires) make up part of the COPD patients' usual health care, there was no need for an ethical committee approval. In the present study, the following precautions were applied: (a) All the patients were individually informed about the study proposes, about their right to refuse to participate and/or to withdraw from participating in the study, and that their data are confidentially protected; and (b) oral consents were taken in the presence of at least one witness.

Sample Size {#section3-1557988320922630}
-----------

The study sample size was estimated using the following predictive equation ([@bibr27-1557988320922630]): *n* = (Z~α/2~^2^ p q)/∆^2^, where "*n*" was the needed number of COPD patients; "Z~α/2~" was the normal deviate for type I error (Z~α/2~ = 1.64 for 10% level of significance); "p" was the population frequency of COPD patients having a "mild or moderate" AFL according to the post-bronchodilator FEV~1%pred~; "q" was equal to "1 − p"; and "∆" was the precision, and it was fixed at 0.11. According to [@bibr36-1557988320922630], among the 1,086 COPD patients, 435 (*p* = 0.40) had a "mild or moderate" AFL. The insertion of the above data in the predictive equation gave a sample size of 53 patients.

Population {#section4-1557988320922630}
----------

The population source involved all the patients referred to the aforementioned department for a spirometric test during the study period. The target population was COPD patients who accepted to be included. The following inclusion criteria were applied: COPD diagnosis, clinically stable COPD, male sex, age ≥40 years, and tobacco use greater than five pack-years. Patients with cognitive disorder or inability to answer the questions adequately were not included.

Used Questionnaires and Applied Definitions {#section5-1557988320922630}
-------------------------------------------

All the COPD patients answered a questionnaire including three parts: a general questionnaire ([@bibr13-1557988320922630]), the CAT ([@bibr25-1557988320922630], [@bibr24-1557988320922630]), and the VQ11 ([@bibr37-1557988320922630], [@bibr38-1557988320922630]) QOL questionnaires. The general questionnaire, inspired by the American Thoracic Society ([@bibr13-1557988320922630]), was utilized to collect the following data: demographic data (socioeconomic and schooling levels, marital status), smoking habits, personal medical and surgical histories, current respiratory symptoms (e.g., cough, sputum, dyspnea), exacerbations, and medications. Two socioeconomic (low \[e.g., unskilled worker, jobless\] and high \[e.g., skilled worker, farmer, manager\]) and schooling (low \[illiterate, primary education\] and high \[secondary and university education\]) levels were arbitrarily determined. The marital status (married, single, divorced, widower) was determined. Tobacco use was evaluated in pack-years. The patients were divided into ex-smokers (patients who stopped smoking 6 months earlier) and current smokers ([@bibr50-1557988320922630]). Dyspnea was evaluated according to the modified British Medical Research Council scale and two levels of dyspnea were arbitrarily defined (mMRC \<2 or ≥2) ([@bibr14-1557988320922630]). The COPD exacerbation was defined as an acute event characterized by deterioration of the patient's respiratory symptoms exceeding normal day-to-day variations and leading to treatment modification (inhaled bronchodilator or corticosteroid, antibiotics) or hospitalization ([@bibr17-1557988320922630]; [@bibr26-1557988320922630]). The validated Arabic version of the CAT was used ([@bibr2-1557988320922630]). This eight-item auto-questionnaire aims to quantify the COPD impacts on the health status ([@bibr2-1557988320922630]; [@bibr25-1557988320922630], [@bibr24-1557988320922630]). The COPD patients were classified into two groups (CAT score \<10 or ≥10). The VQ11, a valid French questionnaire providing a reliable measure of QOL, was applied ([@bibr37-1557988320922630], [@bibr38-1557988320922630]). This questionnaire includes 11 items distributed into three components (functional = 3; psychological = 4; relational = 4). The questions were translated into Arabic (*by* FG *in the authors' list*). The VQ11 score ranges from 11 to 55 and a high score (≥22) indicates low QOL.

Anthropometric Data {#section6-1557988320922630}
-------------------

The decimal age was noted. The height (m) and weight (kg), with heels joined and back straight, were measured using a mechanical scale (Seca Deutschland). The body mass index (BMI, kg/m^2^) was calculated. The following corpulence statuses were categorized: underweight (BMI \<18.5 kg/m^2^), normal weight (BMI: 18.5 to 24.9 kg/m^2^), overweight (BMI: 25.0 to 29.9 kg/m^2^), and obesity (BMI ≥30.0 kg/m^2^; [@bibr57-1557988320922630]).

Spirometric Measurements, COPD Diagnosis, Refined GOLD "ABCD" Classification {#section7-1557988320922630}
----------------------------------------------------------------------------

The spirometric tests were performed by experienced technicians. The acceptability and reproducibility criteria were checked twice by trained residents (*IA and HK* *in the authors list*) based on the international guideline ([@bibr34-1557988320922630]). The pre- and post- bronchodilator-measured spirometric parameters were expressed in percentage of local predictive equations ([@bibr7-1557988320922630]). The FVC maneuver and the bronchodilator test are described elsewhere ([@bibr7-1557988320922630]; [@bibr41-1557988320922630]).

Diagnosis of COPD was determined from a post-bronchodilator FEV~1~/FVC ratio \<0.70 ([@bibr17-1557988320922630]). The refined [@bibr17-1557988320922630] "ABCD" classification was applied. It was based on the patient's health status (mMRC scale or CAT score) and on the history of exacerbations including hospitalization ([@bibr17-1557988320922630]). The four groups (A, B, C, and D) were determined and the COPD patients were classified into two subgroups ("A/B" and "C/D").

FEV~1~ Expressions and AFL Classifications {#section8-1557988320922630}
------------------------------------------

The post-bronchodilator FEV~1~ was expressed in five ways:

1.  (i) FEV~1%pred~: percentage of the local predicted value ([@bibr17-1557988320922630])

2.  (ii) FEV~1z-score~: calculated as (measured minus predicted) divided by the residual standard deviation of the predicted value ([@bibr43-1557988320922630])

3.  (iii) FEV~1~/height^2^: FEV~1~ divided by the squared height ([@bibr36-1557988320922630])

4.  (iv) FEV~1~/height^3^: FEV~1~ divided by the cubed height ([@bibr35-1557988320922630])

5.  (v) FEV~1Quotient~: absolute value of FEV~1~ divided by the sex-specific first percentile (0.5 L for males; [@bibr35-1557988320922630]).

[Box 1](#table4-1557988320922630){ref-type="table"} presents the five AFL classifications, based on the post-bronchodilator FEV~1~. For practical reasons (detailed in the Discussion section), the "mild" and "moderate" AFLs were considered as "light" and the "severe" and "very severe" AFLs were considered as "severe" **([Box 1](#table4-1557988320922630){ref-type="table"})**.

###### 

Numbers of COPD Patients in the Four Severity Stages According to the Five Classifications of AFL.

![](10.1177_1557988320922630-table4)

  -------------------------------------------------------------------------------------------------------
                                                "Light"      "Severe"                        
  --------------------------------------------- ------------ --------------- --------------- ------------
  AFL classifications (reference)                                                            

  FEV~1%pred~ GOLD. (2019)                      ≥80%\        50% to 80%\     30% to 50%\     \<30%\
                                                (*n* = 2)    (*n* = 18)      (*n* = 23)      (*n* = 12)

  FEV~1z-score~ Quanjer et al. (2014)           ≥ −2\        −2 to −3\       −3 to −4\       \< −4\
                                                (*n* = 3)    (*n* = 3)       (*n* = 8)       (*n* = 41)

  FEV~1~/height^2^ [@bibr36-1557988320922630]   ≥0.5\        0.4 to 0.5\     0.3 to 0.4\     \<0.3\
                                                (*n* = 31)   (*n* = 10)      (*n* = 7)       (*n* = 7)

  FEV~1~/height^3^ [@bibr35-1557988320922630]   ≥0.38\       0.29 to 0.38\   0.22 to 0.29\   \<0.22\
                                                (*n* = 18)   (*n* = 14)      (*n* = 11)      (*n* = 12)

  FEV~1Quotient~ [@bibr35-1557988320922630]     ≥3.38\       2.50 to 3.38\   1.90 to 2.50\   \<1.90\
                                                (*n* = 19)   (*n* = 14)      (*n* = 12)      (*n* = 10)
  -------------------------------------------------------------------------------------------------------

*Note*. AFL = airflow limitation; COPD = chronic obstructive pulmonary disease; FEV~1~ = post-bronchodilator forced expiratory volume in 1 s; *n* = number; ~%pred~ = % of the predicted value.

Statistical Analysis {#section9-1557988320922630}
--------------------

The quantitative data were expressed as mean ± standard deviation (95% confidence interval). The qualitative data were expressed by relative frequency. Comparison between the pre- and the post- bronchodilator spirometric parameters was performed using the Wilcoxon test. The comparison between the percentages of COPD patients having "light" or "severe" AFL, based on the retained five classifications, was carried out via the Cochrane test. When applicable, significant differences between the percentages were tested using the McNemar test. The comparisons of the CAT and the VQ11 scores of COPD patients having "light" or "severe" AFL were performed via the Mann Whitney *U* test. The comparisons of the percentages between the "light" and the "severe" AFL groups with regard to the COPD patients having low QOL or belonging to GOLD "C/D" were conducted via the chi-square test. The analyses were carried out using the Statistica software (Statistica Kernel version 6; StatSoft, Paris, France). Alpha was set at *p* \< .05.

Results {#section10-1557988320922630}
=======

Among the 56 examined male COPD patients, only 1 with a cognitive disorder was not included. [Table 1](#table1-1557988320922630){ref-type="table"} presents their descriptive data. The COPD patients age ranged from 48.5 to 82.3 years. The number (%) of overweight or obese patients was 25 (45.5). GOLD B and D dominated the GOLD "ABCD" classification (together, they represented 50 \[90.9%\] patients). [Table 2](#table2-1557988320922630){ref-type="table"} presents the personal medical and surgical histories of the patients.

###### 

Descriptive Data of the 55 COPD Patients.

![](10.1177_1557988320922630-table1)

                                                                                                    Mean ± *SD* or number (%)   95% CI
  ------------------------------------------------------ -------------------- --------------------- --------------------------- ----------------------------------------------------------------------
  **Anthropometric data and obesity status**                                                                                    
  Age (years)                                            65.6 ± 8.1           \[63.4, 67.8\]                                    
  Height (m)                                             1.67 ± 0.06          \[1.65, 1.69\]                                    
  Weight (kg)                                            68 ± 15              \[64, 72\]                                        
  Body mass index (kg/m^2^)                              24.3 ± 5.5           \[22.8, 25.7\]                                    
  Corpulence status                                      Underweight          9 (16.4)                                          
  Normal weight                                          21 (38.2)                                                              
  Overweight                                             19 (34.5)                                                              
  Obesity                                                6 (10.9)                                                               
  **Demographic data and smoking habits**                                                                                       
  Low socioeconomic level                                35 (63.6)                                                              
  Low schooling level                                    45 (81.8)                                                              
  Marital status (married)                               39 (70.9)                                                              
  Tobacco smoking (pack-years)                           67 ± 44              \[55, 79\]                                        
  Current smokers                                        23 (41.8)                                                              
  **GOLD "ABCD" classification, CAT, and VQ11 scores**                                                                          
  GOLD                                                   A                    4 (7.3)                                           
  B                                                      23 (41.8)                                                              
  C                                                      1 (1.8)                                                                
  D                                                      27 (49.1)                                                              
  CAT score                                              20 ±10               \[18, 23\]                                        
  VQ11                                                   Functional           9 ± 3                 \[8, 10\]                   
  Psychologic                                            10 ± 4               \[9, 11\]                                         
  Relational                                             11 ± 4               \[9, 12\]                                         
  Total                                                  30 ± 10              \[27, 33\]                                        
  Low quality of life                                    40 (72.73)                                                             
  Spirometric data                                                                                                              
                                                         Pre-bronchodilator   Post-bronchodilator                               
                                                         Mean ± *SD*          95% CI                Mean ± *SD*                 95% CI
  FEV~1~ (L)                                             1.34 ± 0.51          \[1.21, 1.48\]        1.46 ± 0.52                 \[1.32, 1.60\][\*](#table-fn3-1557988320922630){ref-type="table-fn"}
  FEV~1%pred~                                            40 ± 15              \[36, 44\]            43 ± 16                     \[39, 48\][\*](#table-fn3-1557988320922630){ref-type="table-fn"}
  FVC (L)                                                2.46 ± 0.67          \[2.28, 2.64\]        2.63 ± 0.69                 \[2.45, 2.82\][\*](#table-fn3-1557988320922630){ref-type="table-fn"}
  FVC~%pred~                                             62 ± 16              \[58, 66\]            67 ± 17                     \[62, 71\][\*](#table-fn3-1557988320922630){ref-type="table-fn"}
  FEV~1~/FVC (absolute value)                            0.54 ± 0.09          \[0.51, 0.56\]        0.55 ± 0.10                 \[0.52, 0.57\][\*](#table-fn3-1557988320922630){ref-type="table-fn"}
  FEV~1z-score~ (absolute value)                                                                    −4.68 ± 1.33                \[−5.03, 4.32\]
  FEV~1~/height^2^ (L/m^2^)                                                                         0.52 ± 0.18                 \[0.47, 0.57\]
  FEV~1~/height^3^ (L/m^3^)                                                                         0.31 ± 0.11                 \[0.28, 0.34\]
  FEV~1Quotient~ (absolute value)                                                                   2.92 ± 1.04                 \[2.64, 3.21\]

*Note*. Qualitative data were number (%). Quantitative data were mean ± *SD* (95% confidence interval \[CI\]). CAT = COPD assessment test; COPD = chronic obstructive pulmonary disease; FEV~1~ = forced expiratory volume in 1 s; FVC = forced vital capacity; ~**%**pred~ = percent of the predicted value; VQ11: quality-of-life questionnaire.

*p* \<.05: Wilcoxon test: pre-bronchodilator versus post-bronchodilator.

###### 

Personal Medical and Surgical Histories of the 55 COPD Patients.
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  Medical history                                 
  ------------------------- --------------------- -----------
  Cardiovascular diseases   Stable hypertension   17 (30.9)
  Myocardial infarctions    3 (5.4)               
  Pectoral angina           3 (5.4)               
  Arrhythmias               3 (5.4)               
  Stroke                    3 (5.4)               
  Heart failure             2 (3.6)               
  Total                     31 (56.4)             
  Atopy                     19 (34.5)             
  Dyslipidemia              7 (12.7)              
  Mellitus diabetes         6 (10.9)              
  Neoplasm                  Lung                  2 (3.6)
  Bladder                   1 (1.8)               
  Total                     3 (5.4)               
  Anemia                    2 (3.6)               
  Pulmonary tuberculosis    1 (1.8)               
  Dysthyroidism             1 (1.8)               
  Surgical history                                
  Abdominopelvic matter     10 (18.1)             
  Urologic matter           4 (7.2)               
  Thoracic matter           3 (5.4)               
  Total                     17 (30.9)             

*Note*. Data were number (%). COPD = chronic obstructive pulmonary disease.

[Table 3](#table3-1557988320922630){ref-type="table"} presents the characteristics of COPD patients divided into two groups ("light" vs. "severe") according to the AFL severities. This table main results were the following:

1.  (i) The percentages of patients with "light" or "severe" AFL were significantly influenced by the applied classification (Cochrane test = 91.49, df = 4, *p* \<.05). For the "light" AFL group, the number (%) of patients varied from 6 (10.9%; FEV~1z-score~) to 41 (74.6%; FEV~1~/height^2^). The difference was statistically significant between the FEV~1%pred~ or the FEV~1z-score~ and the remaining four classifications. However, no statistically significant difference was found between FEV~1~/height^^2^^ and FEV~1~/height^3^ or FEV~1Quotient~, or between FEV~1~/height^3^ and FEV~1Quotient~.

2.  (ii) The AFL classification based on FEV~1~/height^2^ and FEV~1Quotient~ did not distinguish the patients according to their CAT scores. For the remaining three classifications, the CAT score of the patients having "severe" AFL was significantly higher than that of the patients having "light" AFL.

3.  (iii) The five AFL classifications distinguished the patients according to their total VQ11 score. The patients having "severe" AFL had a significantly higher score than those having "light" AFL.

4.  (iv) The five AFL classifications distinguished the patients according to their QOL level. The percentages of the patients with low QOL were significantly higher in the "severe" AFL group.

5.  (v) Only the FEV~1Quotient~ AFL classification distinguished the patients according to their GOLD "ABCD" groups. The percentage of the patients belonging to GOLD "C/D" was significantly higher in the "severe" AFL group.

###### 

Characteristics of the 55 COPD Patients Divided According to the Two AFL Severity Stages Defined Using the Post-Bronchodilator FEV~1~ Expressed in Five Ways.
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  FEV~1~ expression   FEV~1%pred~   FEV~1z-score~                                                      FEV~1~/height^2^   FEV~1~/height^3^                                                   FEV~1Quotient~                                                                                                                                                                                                                                   
  ------------------- ------------- ------------------------------------------------------------------ ------------------ ------------------------------------------------------------------ ---------------- ----------------------------------------------------------------- ----------- ------------------------------------------------------------------ ----------- ------------------------------------------------------------------ ---------------------------------------------------------------
  Number (%)          20 (36.4)     35 (63.6)                                                          6 (10.9)           49 (89.1)                                                          41 (74.6)        14 (25.4)                                                         32 (58.2)   23 (41.8)                                                          33 (60.0)   22 (40.0)                                                          [\*](#table-fn8-1557988320922630){ref-type="table-fn"}abcdefg
  CAT score           16 ± 10       23 ± 9^[\#](#table-fn6-1557988320922630){ref-type="table-fn"}^     9 ± 7              22 ± 9^[\#](#table-fn6-1557988320922630){ref-type="table-fn"}^     19 ± 10          24 ± 9                                                            18 ± 9      24 ± 9^[\#](#table-fn6-1557988320922630){ref-type="table-fn"}^     18 ± 9      24 ± 9                                                             
  VQ11 score          23 ± 8        34 ± 9^[\#](#table-fn6-1557988320922630){ref-type="table-fn"}^     19 ± 8             31 ± 10^[\#](#table-fn6-1557988320922630){ref-type="table-fn"}^    27 ± 10          38 ± 7^[\#](#table-fn6-1557988320922630){ref-type="table-fn"}^    25 ± 8      37 ± 9^[\#](#table-fn6-1557988320922630){ref-type="table-fn"}^     25 ± 8      37 ± 9^[\#](#table-fn6-1557988320922630){ref-type="table-fn"}^     
  Low QOL             7 (35.0)      33 (94.3)^[!](#table-fn7-1557988320922630){ref-type="table-fn"}^   1 (16.7)           39 (79.6)^[!](#table-fn7-1557988320922630){ref-type="table-fn"}^   26 (63.4)        14 (100)^[!](#table-fn7-1557988320922630){ref-type="table-fn"}^   18 (56.3)   22 (95.7)^[!](#table-fn7-1557988320922630){ref-type="table-fn"}^   19 (57.6)   21 (95.5)^[!](#table-fn7-1557988320922630){ref-type="table-fn"}^   
  GOLD "C/D"          10 (50.0)     18 (51.4)                                                          4 (66.7)           24 (49.0)                                                          19 (46.3)        9 (64.3)                                                          13 (40.6)   10 (43.5)                                                          13 (39.4)   15 (68.2)^[!](#table-fn7-1557988320922630){ref-type="table-fn"}^   

*Note*. Data were number (%) except for the CAT and VQ11 scores, where data were mean ± *SD*. "Light" AFL includes "mild" and "moderate" AFL. "Severe" AFL includes "severe" and "very severe" AFL. AFL = airflow limitation; CAT = COPD assessment test; COPD = chronic obstructive pulmonary disease; FEV~1~ = forced expiratory volume in 1 s; ~**%**pred~ = percent of the predicted value; QOL = quality-of-life; VQ11: quality-of-life questionnaire.

*p* \< .05 (Mann--Whitney): CAT or VQ11 scores: "light" versus "severe" for the same FEV~1~ expression.

*p* \< .05 (chi-square): low QOL or GOLD "C/D": "light" versus "severe" for the same FEV~1~ expression.

*p* \< .05 (Cochrane Q test): comparison between the % of COPD patients having "light" or "severe" AFL based on the retained five classifications.

McNemar test:

FEV~1%pred~ versus FEV~1z-score~

FEV~1%pred~ versus FEV~1~/height^^2^^

FEV~1%pred~ versus FEV~1~/height^3^

FEV~1%pred~ versus FEV~1Quotient~

FEV~1z-score~ versus FEV~1~/height^^2^^

FEV~1z-score~ versus FEV~1~/height^3^

FEV~1z-score~ versus FEV~1Quotient~

FEV~1~/height^^2^^ versus FEV~1~/height^3^

FEV~1~/height^^2^^ versus FEV~1Quotient~

FEV~1~/height^3^ versus FEV~1Quotient~

Discussion {#section11-1557988320922630}
==========

The present study concluded that the severity of the COPD AFL depended on how the post-bronchodilator FEV~1~ was expressed. First, the percentages of the patients with "light" or "severe" AFL were influenced by the applied classification of the AFL severity. Second, only three AFL classifications (FEV~1%pred~, FEV~1z-score~, and FEV~1~/height^3^) distinguished the patients according to their CAT scores. Third, only the FEV~1Quotient~ AFL classification distinguished the patients according to their GOLD "ABCD" groups. Finally, the five AFL classifications distinguished the patients according to their QOL level (VQ11 score).

To the extent of the authors' knowledge, the present study is the first to raise the issue of the utility of several AFL classifications in terms of the refined "ABCD" assessment tool and in terms of the impacts on the health status. The other related studies aimed to evaluate the performance of some AFL classifications in predicting the survival ([@bibr36-1557988320922630]), the all-cause mortality ([@bibr19-1557988320922630]; [@bibr21-1557988320922630]; [@bibr35-1557988320922630]; [@bibr40-1557988320922630]; [@bibr58-1557988320922630]), or the risk of some clinical outcomes (e.g., severe acute exacerbation \[SAE\], unplanned hospitalization, or physical and mental status decline ([@bibr19-1557988320922630]; [@bibr21-1557988320922630])). [Table S1](https://journals.sagepub.com/doi/suppl/10.1177/1557988320922630) ([Appendix](https://journals.sagepub.com/doi/suppl/10.1177/1557988320922630)) presents the main results of these studies ([@bibr19-1557988320922630]; [@bibr21-1557988320922630]; [@bibr35-1557988320922630]; [@bibr36-1557988320922630]; [@bibr40-1557988320922630]; [@bibr58-1557988320922630]).

Discussion of Results {#section12-1557988320922630}
---------------------

The severity of the COPD AFL depended on how the post-bronchodilator FEV~1~ was expressed ([Table 3](#table3-1557988320922630){ref-type="table"}). The percentages of the patients with "light" or "severe" AFL were influenced by the applied classification ([Table 3](#table3-1557988320922630){ref-type="table"}). Three (FEV~1%pred~, FEV~1z-score~, and FEV~1~/height^3^), one (FEV~1Quotient~), and five (FEV~1%pred~, FEV~1z-score~, FEV~1~/height^^2^^, FEV~1~/height^3^ and FEV~1Quotient~) AFL classifications distinguished the patients according to their CAT scores, their GOLD groups, and their QOL level, respectively ([Table 3](#table3-1557988320922630){ref-type="table"}). The three points mentioned earlier, rarely dealt with in the literature, could influence the adherence of physician to the GOLD guideline. In fact, AFL severity, CAT scores, GOLD "ABCD" groups, and QOL level were shown to be barriers to physicians' guideline adherence ([@bibr31-1557988320922630]). The following text discusses the advantages/disadvantages of the five FEV~1~ expressions/classifications.

The classification based on FEV~1%pred~, by far the most widely used one, has "survived" despite its numerous disadvantages ([@bibr28-1557988320922630]). First, since it is influenced by the patients' anthropometric data ([@bibr36-1557988320922630]), the FEV~1%pred~ classification may misclassify the COPD AFL severity, especially in the elderly ([@bibr15-1557988320922630]). Second, since it is not based on statistical evidence, the recommended AFL severity thresholds were arbitrarily chosen ([@bibr28-1557988320922630]; [@bibr59-1557988320922630]). To overcome the FEV~1%pred~ limitations, the z-score method was proposed ([@bibr44-1557988320922630], [@bibr43-1557988320922630]). The z-score, which accounts for the age-related differences in pulmonary function, is free from bias related to the patients' ethnicity and/or anthropometric data ([@bibr15-1557988320922630]). Moreover, staging the COPD AFL severity using the FEV~1z-score~ was associated with all-cause mortality and respiratory symptoms ([@bibr15-1557988320922630]). A recent study, involving older people, compared the proportion of deaths attributed to a reduced FEV~1~, when staged by FEV~1%pred~ (Stages 1 \[≥80%\], 2 \[50%--79%\], and 3 \[\<50%\]) and FEV~1z-score~ (Stages 1 \[≥ −1.64\], 2 \[−2.55 to −1.63\], and 3 \[\< −2.55\]; [@bibr60-1557988320922630]). It appears that the "proportion of deaths attributed to a reduced FEV~1~ is best stratified by z-score staging thresholds" ([@bibr60-1557988320922630]). In the present study, both FEV~1z-score~ and FEV~1%pred~ classifications were effective when comparing the patients according to their CAT and VQ11 scores, but not according to GOLD "C/D" ([Table 3](#table3-1557988320922630){ref-type="table"}). Yet, the z-score method still requires the estimation of a predicted value ([@bibr36-1557988320922630]), which is considered as a limitation. To address the bias resulting from the anthropometric data (FEV~1%pred~ classification; \[[@bibr17-1557988320922630]\]) or the need for a reference equation (FEV~1%pred~ \[[@bibr17-1557988320922630]\] and FEV~1z-score~ \[[@bibr43-1557988320922630]\] classifications), three additional methods (FEV~1~/height^2^, FEV~1~/height^3^, and FEV~1Quotient~) were advanced. In this study, both FEV~1~/height^2^ and FEV~1~/height^3^ classifications distinguished the patients according to their VQ11 scores and QOL status ([Table 3](#table3-1557988320922630){ref-type="table"}). The FEV~1~/height^2^, first described as a predictor of mortality ([@bibr51-1557988320922630]), was then proposed as a COPD staging method ([@bibr36-1557988320922630]). The FEV~1~/height^2^ classification was a good predictor of all-cause mortality and survival ([@bibr21-1557988320922630]; [@bibr35-1557988320922630]). It was a better tool than FEV~1%pred~ for expressing lung function deficiency ([@bibr36-1557988320922630]). Compared to the classification based on the FEV~1%pred~, [@bibr36-1557988320922630] reported that the one based on FEV~1~/height^2^ classified more patients as having "light" AFL (40.05% and 54.14%, respectively; [Table S1](https://journals.sagepub.com/doi/suppl/10.1177/1557988320922630)). The FEV~1~/height^3^ classification, compared to the others (FEV~1%pred~, FEV~1z-scores~) has two advantages. First, it has a satisfactory model for predicting survival, hospitalization, physical and mental decline, as well as SAE risk ([@bibr19-1557988320922630]; [@bibr21-1557988320922630]; [@bibr35-1557988320922630]; [@bibr58-1557988320922630]). Second, it takes into account the body size variability and does not require reference equations ([@bibr58-1557988320922630]). However, its capacity to predict mortality is controversial ([@bibr21-1557988320922630]; [@bibr40-1557988320922630]). In this study, although it did not distinguish the patients according to their CAT scores, FEV~1Quotient~ was the only classification that differentiated the patients according to the GOLD "C/D" ([Table 3](#table3-1557988320922630){ref-type="table"}). This classification, first introduced as an alternative to expressing lung function deficiency ([@bibr35-1557988320922630]), has been the best model for predicting survival. It outperformed the other classifications in predicting the risk of SAE, hospitalization, as well as physical and mental decline ([@bibr19-1557988320922630]; [@bibr21-1557988320922630]; [@bibr35-1557988320922630]; [@bibr40-1557988320922630]).

Discussion of Methodology {#section13-1557988320922630}
-------------------------

Unlike the six aforementioned studies ([@bibr19-1557988320922630]; [@bibr21-1557988320922630]; [@bibr35-1557988320922630]; [@bibr36-1557988320922630]; [@bibr40-1557988320922630]; [@bibr58-1557988320922630]; [Table S1](https://journals.sagepub.com/doi/suppl/10.1177/1557988320922630)), the present study opted for a prospective design. This enables describing the disease characteristics in a population over a period of time (1 year for this study). When compared to prospective studies, retrospective ones have some disadvantages ([@bibr20-1557988320922630]). First, their level of evidence is low ([@bibr20-1557988320922630]). Second, the selection of the control group may be significantly biased ([@bibr20-1557988320922630]) and therefore it cannot be representative of the population ([@bibr47-1557988320922630]). Third, their outcomes assessment is poorly controlled ([@bibr54-1557988320922630]). Fourth, they require very large sample sizes ([@bibr20-1557988320922630]).

In the present study, the COPD patients had almost the same profile observed in real practice in Tunisia (e.g., mean age, smoking habits, and corpulence status; [Table 1](#table1-1557988320922630){ref-type="table"} \[[@bibr5-1557988320922630], [@bibr4-1557988320922630]; [@bibr8-1557988320922630], [@bibr6-1557988320922630]; [@bibr30-1557988320922630]; [@bibr45-1557988320922630]\]). For example, the mean age of the present study patients (66 ± 8 years) was similar to that of COPD patients included in two previous local studies (e.g., 63 ± 9 years \[[@bibr8-1557988320922630]\]; 60 ± 10 years \[[@bibr30-1557988320922630]\]). Moreover, the mean age of this study's COPD patients and their smoking habits were intermediate compared with those reported in similar studies ([Table S1](https://journals.sagepub.com/doi/suppl/10.1177/1557988320922630)).

Similar to this study, some others also used the post-bronchodilator parameters ([@bibr36-1557988320922630], [@bibr35-1557988320922630]; [@bibr40-1557988320922630]). However, while Huang et al. ([@bibr21-1557988320922630]) used the post-bronchodilator parameters only if available, some other authors ([@bibr19-1557988320922630]; [@bibr58-1557988320922630]) opted for the pre-bronchodilator ones. This makes the comparison between the studies difficult since there are big differences between the pre- and post-bronchodilator parameters ([@bibr22-1557988320922630]; [@bibr42-1557988320922630]). In this study, as suggested by [@bibr17-1557988320922630], COPD diagnosis was retained when the postbronchodilator FEV~1~/FVC ratio was \<0.70. In similar studies, the COPD diagnosis criterion was not mentioned in two studies ([@bibr19-1557988320922630]; [@bibr58-1557988320922630]), and it was different in some others (post-bronchodilator FEV~1~/FVC ratio \< lower limit of normal \[[@bibr21-1557988320922630]; [@bibr40-1557988320922630]\]; FEV~1~/FVC ratio \<89% \[[@bibr35-1557988320922630]; [@bibr36-1557988320922630]\]).

Similar to other related studies ([Table S1](https://journals.sagepub.com/doi/suppl/10.1177/1557988320922630)) and as recommended by scholarly societies ([@bibr1-1557988320922630]; [@bibr10-1557988320922630]; [@bibr17-1557988320922630]; [@bibr39-1557988320922630]; [@bibr52-1557988320922630]; [@bibr62-1557988320922630]), grading the severity of COPD AFL in this study was based on the FEV~1~. The latter is correlated with COPD severity ([@bibr52-1557988320922630]), the number of exacerbations ([@bibr48-1557988320922630]), and the impacts on QOL ([@bibr29-1557988320922630]). The FEV~1~ is considered as a predictor of mortality ([@bibr3-1557988320922630]; [@bibr49-1557988320922630]; [@bibr56-1557988320922630]). Some authors ([@bibr11-1557988320922630]) proposed a new AFL classification based on the FEV~1~/FVC ratio. The latter seemed to be less dependent on ethnicity. It agreed moderately with the FEV~1%pred~-based classification and gave similar results in terms of QOL, dyspnea, and number of exacerbations ([@bibr11-1557988320922630]).

Considering the "mild" and "moderate" AFLs as "light" and the "severe" and "very severe" AFLs as "severe" ([Box 1](#table4-1557988320922630){ref-type="table"}) was due to two "practical reasons" related to the small subsample sizes and to a statistical ease. First, in some AFL severity stages, the number of COPD patients was very small (*n* = 2 for the FEV~1%pred~ mild stage, *n* = 3 for the FEV~1z-score~ mild and moderate stages; [Box 1](#table4-1557988320922630){ref-type="table"}). Second, dealing with four stages of AFL in a single study seems to be difficult. This raises some questions, such as whether the frequencies of some epidemiological and/or clinical data (e.g., corpulence status, QOL levels, CAT scores) in those stages are comparable.

According to the 2001 classification of the World Health Organization, the natural evolution of COPD has three phases: deficiency, incapacity, and social disadvantage [@bibr61-1557988320922630]. In practice, the assessment of the last phase is based on quantifying the QOL impairment via some specific questionnaires ([@bibr23-1557988320922630]). In this study, the CAT ([@bibr25-1557988320922630]) and the VQ11 ([@bibr37-1557988320922630], [@bibr38-1557988320922630]) questionnaires were chosen for two reasons. First, these two questionnaires are easier and less time-consuming than other questionnaires and they have simple scoring algorithms ([@bibr24-1557988320922630]; [@bibr38-1557988320922630]). Second, their scores are well correlated with the COPD AFL severity ([@bibr16-1557988320922630]; [@bibr38-1557988320922630]).

The present study has three main limitations. First, the number of included COPD patients (*n* = 55) "seems" to be relatively low, when compared to similar studies, where *n* varied from 296 ([@bibr21-1557988320922630]) to 1,095 ([@bibr35-1557988320922630]; [@bibr36-1557988320922630]; [Table S1](https://journals.sagepub.com/doi/suppl/10.1177/1557988320922630)). This study's sample size was calculated according to a predictive equation ([@bibr27-1557988320922630]). In practice, calculating the required minimal sample size, a statistically fundamental point for planning a study protocol, provides the study with a sufficient statistical power ([@bibr27-1557988320922630]). For that reason, this study sample size was closer to the database size (*n* = 54) used by some authors ([@bibr19-1557988320922630]; [@bibr58-1557988320922630]; [Table S1](https://journals.sagepub.com/doi/suppl/10.1177/1557988320922630)). Second, the convenience sampling might weaken the ability to make generalizations from the present sample to the general population. Third, the diagnosis of cognitive disorder was subjective. It could have been better if an objective tool such as the Mini-Mental State Examination was applied ([@bibr55-1557988320922630]).

To conclude, the five classifications of COPD AFL were not similar when compared with regard to some relevant male health outcomes. Therefore, further studies, including large sample sizes, to determine the best method for staging COPD AFL severity should be conducted. Moreover, a global consensus on how to stage COPD AFL should be advanced.
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